PONTE
VEDRA, Fla., Aug. 1, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD)
a biopharmaceutical company focused on developing tecarfarin, a
late-stage novel oral and reversible anticoagulant (blood thinner)
for certain rare medical conditions, today announced that the
Company is expanding its focus for tecarfarin to patients with
implanted medical devices for heart diseases who are struggling
with the lack of effective anticoagulant treatment options.
Based on clinical data, market research, and insights from key
industry experts, the Company believes this approach may be a
potential additional indication for tecarfarin.
"The goal for Cadrenal is to advance tecarfarin in targeted
indications where Vitamin K antagonists (warfarin) are prescribed
yet have failed to achieve sufficiently reliable anticoagulation,"
commented Quang Pham, CEO of
Cadrenal Therapeutics. "Patients with implanted medical devices
such as left ventricular assist devices (LVADs) struggle with
warfarin due to the way in which it is metabolized, resulting in
suboptimal anticoagulation. Tecarfarin is specifically designed to
solve warfarin's metabolism problem via an alternate pathway that
is abundant and essentially insaturable, providing a much more
reliable pharmacokinetic profile. We look forward to expanding our
focus for tecarfarin within this patient population."
Based on Cadrenal market research, there are estimated to be
12,000 patients in the U.S. with LVADs who struggle with stable
anticoagulation with warfarin. Based on Company estimates, this
would translate into an addressable market opportunity of
approximately U.S. $600 million per
year. The direct-acting oral anticoagulants such as Eliquis and
Xarelto are not prescribed for these patients.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin, a late-stage
novel oral and reversible anticoagulant (blood thinner) with orphan
drug and Fast Track designations for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage kidney disease, or ESKD, and atrial fibrillation.
Tecarfarin is specifically designed to leverage a different
metabolism pathway than the oldest and most commonly prescribed
Vitamin K antagonist (warfarin) used in the prevention of
thrombosis. Tecarfarin has been evaluated in eleven (11) human
clinical trials and more than 1,000 individuals. In Phase 1, Phase
2, and Phase 2/3 clinical trials, tecarfarin has generally been
well-tolerated in both healthy adult subjects and patients with
chronic kidney disease (CKD). For more information, please
visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding the approach being a potential additional indication for
tecarfarin, expanding the Company's focus for tecarfarin
within patients with implanted medical devices for heart diseases,
the estimated 12,000 patients in the U.S. with LVADs who
struggle with stable anticoagulation with warfarin and the
estimated addressable market opportunity of approximately U.S.
$600 million per year. The words
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the ability to expand the Company's focus to
patients with implanted medical devices for heart diseases, the
ability to penetrate the U.S. market for patients with LVADs who
struggle with stable anticoagulation with warfarin and the ability
to advance patient care in cardiorenal diseases and the other risk
factors described in the Company's Annual Report on Form 10-K for
the year ended December 31, 2022, and
the Company's subsequent filings with the SEC, including subsequent
periodic reports on Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. Any forward-looking statements contained in
this press release speak only as of the date hereof and, except as
required by federal securities laws, the Company specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-expands-focus-for-tecarfarin-to-patients-with-implanted-medical-devices-for-heart-diseases-301889909.html
SOURCE Cadrenal Therapeutics, Inc.